Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-74
SponsorUniversity of Turku
About this trial
The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
The body mass index must be below 35
Age < 18 or > 74
The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.
Trial population
Adult patients of the HUS (Joint Authority of the Helsinki and Uusimaa Hospital District) Center of Arthroplasty and the Orto Surgical Hospital of Turku University.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Total hip arthroplasty
Procedure/SurgeryHip joint replacement surgery. Elective for RA and OA cases.
Treatment groups
110 Participants
are divided into 3 treatment groupsGroup A: OA cases1 intervention
Group B: RA cases1 intervention
Group C: Non-arthritic controls1 intervention
Trial outcomes
Primary outcomes
1
Characterization of cell populations in OA
Characterization of cell populations found in different synovial tissues and blood derived samples of OA patients utilising single-cell RNA sequencing solutions.
Time frame
Starting during the first quarter of 2025, ending by the last quarter of 2026.2
Comparison of cell populations between OA cases and controls
The investigators will determine how the cell composition differs between arthritic and corresponding non-arthritic tissues utilising single-cell RNA sequencing solutions.
Time frame
Starting during the first quarter of 2025, ending by the last quarter of 2026.3
Cellular landscape in OA
The investigators will map the transcriptional, regulatory and protein landscape of OA at single-cell and tissue (spatial) level.
Time frame
Starting during the last quarter of 2024, ending by the last quarter of 2026.4
Key molecular pathways of OA
The investigators will determine what are the key molecular pathways activated in OA.
Time frame
Starting during the last quarter of 2025, ending by the last quarter of 2027.Secondary outcomes
1
Biomarkers for OA
The investigators will investigate if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA.
Time frame
Starting during the second half of 2026, ending by the last quarter of 2028.2
OA endotypes
The investigators aim to identify and further differentiate OA endotypes by utilizing the single-cell and spatial data.
Time frame
Starting during the first half of 2025, ending by the second half of 2027.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Turku
Lead sponsor
Turku University Hospital
Collaborator
Hospital District of Helsinki and Uusimaa
Collaborator
Source ClinicalTrials.gov